Squawk on the Street Cramer's Morning Take: Eli Lily 5/1/25
May 1, 2025
Discover why investors are urged to hold on to Eli Lilly stocks. Dive into the company's financial performance and the impact of CVS's partnership with Novo Nordisk on the market. Explore the exciting potential of Eli Lilly's new obesity pill, Orphaglipron, as discussions revolve around strategies for managing recent stock volatility. Join the conversation for insights that can help steer your investment decisions.
AI Snips
Chapters
Transcript
Episode notes
Impact of CVS on Eli Lilly Stock
- Eli Lilly's good quarterly results are overshadowed by CVS's decision to prioritize a competitor's GLP-1 obesity drug.
- However, Lilly's obesity pill Orphaglipron offers oral dosing and easier storage, making it competitive worldwide.